By VC News Daily
CAMBRIDGE, MA, Brixton Biosciences, a clinical stage life sciences company, announced that it closed a Series B funding round of $33M.
Brixton Biosciences, a spin-out from Massachusetts General Brigham and a clinical stage life sciences company developing novel therapies for chronic and acute pain, announced that it closed a Series B funding round of $33M. The round was led by Schooner Capital with notable participation by SV Health Investors, Sparta Group, Excelestar Ventures, PV Capital Management, and Catalyst Health Ventures.
(c) by Massinvestor, Inc. For contact info, please check out our about page.